Cetraxate
Chemical compound
- none
- In general: ℞ (Prescription only)
- 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
- 34675-84-8
- 2680
- 2579
- 5VPA8CPF0N
- D07663
- ChEMBL502896
- DTXSID60860400 DTXSID2040658, DTXSID60860400
- Interactive image
- O=C(O)CCc2ccc(cc2)OC(=O)C1CCC(CN)CC1
Cetraxate (INN) is an oral gastrointestinal medication which has a cytoprotective effect.[1][2]
References
- ^ Kurebayashi Y, Ikeda T, Osada Y (January 1988). "Cytoprotective action of cetraxate against HCl.ethanol-induced gastric lesion in rats". Jpn. J. Pharmacol. 46 (1): 17–25. doi:10.1254/jjp.46.17. PMID 3367546.
- ^ Ishimori A, Yamagata S, Taima T (1979). "Effect of p-hydroxyphenyl-propionic ester of tranexamic acid hydrochloride (Cetraxate) on peptic ulcer. Multi-center clinical study". Arzneimittelforschung. 29 (10): 1625–32. PMID 391240.
- v
- t
- e
Drugs for peptic ulcer and GERD/GORD (A02B)
analogues ("-prost-")
("-prazole")
acid blockers ("-prazan")
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
- See also: Helicobacter pylori eradication protocols
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e